Edwards Lifesciences Corp (NYSE:EW) CEO Michael A. Mussallem sold 22,850 shares of the stock in a transaction on Wednesday, June 12th. The shares were sold at an average price of $184.27, for a total value of $4,210,569.50. Following the completion of the sale, the chief executive officer now directly owns 95,770 shares of the company’s stock, valued at $17,647,537.90. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.
Shares of NYSE:EW opened at $183.93 on Friday. The firm has a market capitalization of $38.35 billion, a price-to-earnings ratio of 39.13, a price-to-earnings-growth ratio of 2.36 and a beta of 0.85. The company has a quick ratio of 2.69, a current ratio of 3.66 and a debt-to-equity ratio of 0.19. Edwards Lifesciences Corp has a 1 year low of $134.53 and a 1 year high of $197.86.
Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Tuesday, April 23rd. The medical research company reported $1.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.23 by $0.09. The firm had revenue of $993.00 million during the quarter, compared to the consensus estimate of $989.87 million. Edwards Lifesciences had a return on equity of 31.16% and a net margin of 20.03%. The business’s revenue for the quarter was up 11.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.22 EPS. On average, equities analysts forecast that Edwards Lifesciences Corp will post 5.29 EPS for the current fiscal year.
A number of equities research analysts recently commented on the company. Zacks Investment Research raised Edwards Lifesciences from a “hold” rating to a “buy” rating and set a $199.00 price target for the company in a research report on Thursday, May 9th. Deutsche Bank increased their price target on Edwards Lifesciences from $164.00 to $184.00 and gave the company a “hold” rating in a research report on Wednesday, April 24th. Jefferies Financial Group increased their price target on Edwards Lifesciences from $195.00 to $210.00 and gave the company a “buy” rating in a research report on Wednesday, April 24th. BMO Capital Markets increased their price target on Edwards Lifesciences to $204.00 and gave the company an “outperform” rating in a research report on Friday, March 22nd. Finally, BTIG Research reissued a “hold” rating on shares of Edwards Lifesciences in a research report on Wednesday, April 24th. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and fourteen have given a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $186.52.
Large investors have recently made changes to their positions in the business. Executive Wealth Management LLC bought a new position in shares of Edwards Lifesciences during the 4th quarter worth $25,000. FTB Advisors Inc. bought a new position in shares of Edwards Lifesciences during the 1st quarter worth $25,000. Sontag Advisory LLC bought a new position in shares of Edwards Lifesciences during the 4th quarter worth $26,000. Lindbrook Capital LLC bought a new position in shares of Edwards Lifesciences during the 4th quarter worth $27,000. Finally, Capital Financial Planning LLC bought a new position in shares of Edwards Lifesciences during the 4th quarter worth $28,000. Hedge funds and other institutional investors own 82.12% of the company’s stock.
TRADEMARK VIOLATION WARNING: This story was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this story on another website, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The original version of this story can be read at https://www.dispatchtribunal.com/2019/06/15/edwards-lifesciences-corp-nyseew-ceo-michael-a-mussallem-sells-22850-shares.html.
Edwards Lifesciences Company Profile
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.
Featured Story: Google Finance Portfolio
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.